Merck delivered first-quarter results that exceeded market expectations, fueled by robust sales of its cancer immunotherapy Keytruda and a growing portfolio of newer products.
The company also adjusted its 2026 sales guidance, narrowing the range while simultaneously raising its adjusted profit outlook.
The revised guidance reflects a combination of strong underlying business performance and favorable foreign exchange conditions.
Merck's shares responded positively to the earnings report, with investors reacting to the improved profit forecast and the company's ability to outperform estimates.
The stock's performance highlights the market's focus on Merck's product pipeline and its capacity to maintain growth amid competitive pressures.
The pharmaceutical sector has been under pressure in recent months due to pricing constraints and regulatory scrutiny, but Merck's results suggest that its key products are holding up well.